Jupiter Asset Management Ltd. acquired a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) during the third quarter, HoldingsChannel.com reports. The fund acquired 40,420 shares of the company’s stock, valued at approximately $3,636,000.
Several other large investors have also recently bought and sold shares of FLGT. IFP Advisors Inc lifted its position in shares of Fulgent Genetics by 88.8% during the 3rd quarter. IFP Advisors Inc now owns 287 shares of the company’s stock valued at $26,000 after acquiring an additional 135 shares during the period. JFS Wealth Advisors LLC acquired a new position in shares of Fulgent Genetics during the 3rd quarter valued at $27,000. FMR LLC lifted its position in shares of Fulgent Genetics by 57.5% during the 2nd quarter. FMR LLC now owns 315 shares of the company’s stock valued at $29,000 after acquiring an additional 115 shares during the period. Hexagon Capital Partners LLC acquired a new position in shares of Fulgent Genetics during the 2nd quarter valued at $37,000. Finally, Banque Cantonale Vaudoise acquired a new position in shares of Fulgent Genetics during the 2nd quarter valued at $40,000. 37.70% of the stock is currently owned by institutional investors.
In other Fulgent Genetics news, insider Hanlin Gao sold 311 shares of the stock in a transaction dated Tuesday, November 16th. The shares were sold at an average price of $95.50, for a total transaction of $29,700.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Paul Kim sold 620 shares of the stock in a transaction dated Thursday, December 2nd. The stock was sold at an average price of $83.16, for a total transaction of $51,559.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,736 shares of company stock valued at $350,066. Company insiders own 31.00% of the company’s stock.
NASDAQ FLGT opened at $79.96 on Friday. Fulgent Genetics, Inc. has a 1 year low of $62.50 and a 1 year high of $189.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.23 and a quick ratio of 4.23. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of 4.16 and a beta of 1.33. The company has a fifty day moving average price of $90.01 and a 200-day moving average price of $89.22.
Fulgent Genetics (NASDAQ:FLGT) last posted its earnings results on Tuesday, November 9th. The company reported $3.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $2.63. Fulgent Genetics had a net margin of 54.96% and a return on equity of 67.68%. The firm had revenue of $227.87 million during the quarter, compared to analyst estimates of $264.00 million. On average, research analysts anticipate that Fulgent Genetics, Inc. will post 15.58 EPS for the current fiscal year.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.
Further Reading: Guidelines for Successful Channel Trading
Want to see what other hedge funds are holding FLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulgent Genetics, Inc. (NASDAQ:FLGT).
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.